about
CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)Immunotherapy of Childhood SarcomasProtein glycosylation in cancers and its potential therapeutic applications in neuroblastomaCD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaRevving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Challenges and opportunities of allogeneic donor-derived CAR T cellsEx vivo induction of antitumor DEC-205(+) CD11c(+) cells in a murine neuroblastoma model by co-stimulation with doxorubicin, lipopolysaccharide and interleukin-4Future directions in the treatment of osteosarcoma.Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects.CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia.Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015.Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells.Novel insights and therapeutic interventions for pediatric osteosarcoma.Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.Unleashing the immune response against childhood solid cancers.Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance.Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States.Targeting P-selectin blocks neuroblastoma growth.Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.Agents in Development for Childhood Acute Lymphoblastic Leukemia.A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle.Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells.
P2860
Q26783433-5EA997DE-04DF-4E3A-AB7E-9D4F83F5519BQ26795369-C9EAA048-8188-408A-91AB-476070CE6965Q28069952-300CFC03-D58D-467B-8676-961BED4F3FA0Q28084879-F0C23EB6-1C95-4FFB-922B-3CB486B9F190Q35600095-3CF7CA43-6A26-4DAB-9385-02327E9E9E90Q36257036-13293478-1589-4553-981E-2576CE38F578Q36502098-80A67C93-C026-42D2-A5FD-BA2664D88489Q36600800-09EFA138-8322-453D-BEC7-F87959E61565Q36675086-5C708BEC-36A8-42DA-80B4-3CECD29A3E43Q37153598-BBA6BA18-5B8F-4BBE-AAF5-BCA13FD36D27Q38336989-75D5431C-5439-4D01-8F88-97EAAC3D96F2Q38371387-B8C55C1F-17E6-46FE-86E4-DD664F7923EBQ38635452-BEDC6351-D56D-4708-897E-4432275ADFA9Q38643567-B984321D-4FCD-46DE-ACA0-46FAFF4BADAEQ38759754-11DCA65A-E66A-4C7F-9588-888F09ACE0A2Q38805206-F31175AA-CFFC-4CA6-A7FA-3E8271208B90Q38819276-F8D86240-D371-455C-B6EB-67020E729FD1Q38855717-737AA2A6-6465-4BC6-A4FD-E66ADB3288CBQ39224315-C9C20E95-F2FB-4316-A302-7009499EC6DCQ39253341-CB37AA1D-8F48-47D4-B868-E6EDBB2A89C5Q41979757-2BB8F9CB-AD57-4B07-9141-6F03FC891753Q42697385-6255756B-7D30-4DED-9293-EEB8ACD9EFD5Q47144790-BD04F7B4-D36F-4200-8B6E-A81F7C22779DQ47832898-61276DB6-053C-4878-8E9A-76837A4DE09EQ47837260-F475C44E-5C54-4463-B0CD-8A5377FE3B2AQ49404911-A4373DCE-5A6F-45BF-94E8-458F99FD468DQ50036381-3D409321-06CA-481B-A94C-361CCF36C2A9Q54105269-1E86D4C0-E121-4D4B-BB01-B4BF09477A37
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Immune-based therapies for childhood cancer.
@en
type
label
Immune-based therapies for childhood cancer.
@en
prefLabel
Immune-based therapies for childhood cancer.
@en
P2093
P2860
P1476
Immune-based therapies for childhood cancer
@en
P2093
Crystal L Mackall
Melinda S Merchant
Terry J Fry
P2860
P304
P356
10.1038/NRCLINONC.2014.177
P407
P577
2014-10-28T00:00:00Z